- Investing Ideas
- /
- Swiss Pharmaceuticals & Biotech Strong Balance Sheet Stocks
Swiss Pharmaceuticals & Biotech Strong Balance Sheet Stocks
Results
17
Strong Balance Sheet Stocks: companies with a Health score of at least 4, ordered by Health score.
17 companies
Bachem Holding
Market Cap: CHF 4.4b
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.
BANB
CHF 58.15
7D
-10.7%
1Y
-18.2%
Basilea Pharmaceutica
Market Cap: CHF 565.8m
A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.
BSLN
CHF 46.05
7D
0.9%
1Y
-2.2%
Cosmo Pharmaceuticals
Market Cap: CHF 1.0b
Focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.
COPN
CHF 63.50
7D
-5.6%
1Y
-17.3%
Molecular Partners
Market Cap: CHF 107.7m
A clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.
MOLN
CHF 2.88
7D
2.1%
1Y
-28.0%
Relief Therapeutics Holding
Market Cap: CHF 37.8m
A biopharmaceutical company, engages in identification, development, and commercialization of novel, patent protected products for the treatment of dermatological, metabolic, and pulmonary rare diseases.
RLF
CHF 3.00
7D
0.7%
1Y
11.1%
Tecan Group
Market Cap: CHF 1.9b
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.
TECN
CHF 149.40
7D
-5.7%
1Y
-45.8%
SKAN Group
Market Cap: CHF 1.2b
Provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally.
SKAN
CHF 53.50
7D
-7.8%
1Y
-32.4%
Kuros Biosciences
Market Cap: CHF 878.1m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
KURN
CHF 22.74
7D
-4.1%
1Y
22.8%
Dottikon ES Holding
Market Cap: CHF 4.2b
Manufactures and sells performance chemicals, intermediates, and active pharmaceutical ingredients for the chemical, biotech, and pharmaceutical maceutic industries worldwide.
DESN
CHF 303.00
7D
2.5%
1Y
19.5%
BioVersys
Market Cap: CHF 168.9m
A clinical stage biopharmaceutical company, focuses on identification, development, and commercialization of novel antibacterial products for serious life-threatening infections caused by multi-drug-resistant bacteria.
BIOV
CHF 28.90
7D
-7.7%
1Y
n/a
Galderma Group
Market Cap: CHF 32.1b
Operates as a dermatology company worldwide.
GALD
CHF 135.30
7D
-5.9%
1Y
71.3%
Roche Holding
Market Cap: CHF 218.8b
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.
ROG
CHF 255.00
7D
-2.5%
1Y
-5.8%
Addex Therapeutics
Market Cap: CHF 6.5m
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland.
ADXN
CHF 0.066
7D
-2.1%
1Y
-8.5%
Lonza Group
Market Cap: CHF 36.4b
Supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.
LONN
CHF 518.00
7D
-4.7%
1Y
-4.1%
Siegfried Holding
Market Cap: CHF 3.4b
Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.
SFZN
CHF 78.20
7D
-7.6%
1Y
-32.7%
Newron Pharmaceuticals
Market Cap: CHF 209.6m
A biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States.
NWRN
CHF 10.50
7D
1.0%
1Y
39.6%
PolyPeptide Group
Market Cap: CHF 791.8m
Operates as a contract development and manufacturing company in Europe, the United States, and India.
PPGN
CHF 24.00
7D
-8.0%
1Y
-24.1%